Oryzon Genomics S.A. (ORYZF)

Oryzon Genomics Statistics

Total Valuation

Oryzon Genomics has a market cap or net worth of 235.01 million. The enterprise value is 247.02 million.

Market Cap	235.01M
Enterprise Value	247.02M

Important Dates

The last earnings date was Friday, May 9, 2025.

Earnings Date	May 9, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	77.51M
Shares Outstanding	n/a
Shares Change (YoY)	+5.77%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	62.25M

Valuation Ratios

PE Ratio	n/a
Forward PE	6.58
PS Ratio	29.55
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-54.18
EV / Sales	29.62
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

Current Ratio	n/a
Quick Ratio	n/a
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-3.56

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	n/a
Return on Invested Capital (ROIC)	n/a
Return on Capital Employed (ROCE)	n/a
Revenue Per Employee	169,228
Profits Per Employee	-96,995
Employee Count	47
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +114.89% in the last 52 weeks. The beta is 0.38, so Oryzon Genomics's price volatility has been lower than the market average.

Beta (5Y)	0.38
52-Week Price Change	+114.89%
50-Day Moving Average	n/a
200-Day Moving Average	n/a
Relative Strength Index (RSI)	59.61
Average Volume (20 Days)	3,796

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Oryzon Genomics had revenue of 7.95 million and -4.56 million in losses. Loss per share was -0.07.

Revenue	7.95M
Gross Profit	7.63M
Operating Income	-5.12M
Pretax Income	-6.62M
Net Income	-4.56M
EBITDA	-4.99M
EBIT	-5.12M
Loss Per Share	-0.07

Balance Sheet

Cash & Cash Equivalents	n/a
Total Debt	n/a
Net Cash	n/a
Net Cash Per Share	n/a
Equity (Book Value)	n/a
Book Value Per Share	n/a
Working Capital	n/a

Cash Flow

Operating Cash Flow	n/a
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Margins

Gross margin is 95.89%, with operating and profit margins of -64.40% and -57.32%.

Gross Margin	95.89%
Operating Margin	-64.40%
Pretax Margin	-83.22%
Profit Margin	-57.32%
EBITDA Margin	-62.70%
EBIT Margin	-64.40%
FCF Margin	n/a

Dividends & Yields

Oryzon Genomics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-5.77%
Shareholder Yield	n/a
Earnings Yield	-1.94%
FCF Yield	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	n/a